CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US patent 7,115,579 (the ‘579 patent) for a method of inducing an immune response via administration of certain compounds that act through Toll-like Receptors (TLRs). The claims of this patent, entitled “Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides” cover the administration of selected immune modulatory oligonucleotides through various routes. The compositions of the compounds claimed in the ‘579 patent are covered in several of Idera’s patents and patent applications, including EU1,278,761 and AU2001257366.
